Two Sigma Investments LP Raises Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB)

Two Sigma Investments LP grew its position in shares of PDS Biotechnology Co. (NASDAQ:PDSB) by 273.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 65,732 shares of the company’s stock after acquiring an additional 48,132 shares during the quarter. Two Sigma Investments LP owned about 0.18% of PDS Biotechnology worth $107,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PDSB. Raymond James Financial Inc. purchased a new stake in PDS Biotechnology during the fourth quarter valued at $26,000. Jane Street Group LLC bought a new stake in shares of PDS Biotechnology in the 4th quarter worth about $58,000. Marshall Wace LLP raised its position in shares of PDS Biotechnology by 38.4% during the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after buying an additional 10,837 shares in the last quarter. Virtu Financial LLC bought a new position in shares of PDS Biotechnology in the 4th quarter valued at about $89,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of PDS Biotechnology by 331.0% in the 4th quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock valued at $163,000 after acquiring an additional 76,800 shares during the last quarter. 26.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of PDS Biotechnology in a research note on Wednesday. Wall Street Zen upgraded PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, May 24th.

PDS Biotechnology Trading Up 2.3%

Shares of PDSB opened at $1.79 on Friday. PDS Biotechnology Co. has a twelve month low of $0.85 and a twelve month high of $4.42. The company has a market cap of $81.82 million, a P/E ratio of -1.54 and a beta of 1.27. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. The company’s fifty day simple moving average is $1.33 and its 200-day simple moving average is $1.47.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.04. As a group, analysts expect that PDS Biotechnology Co. will post -1.2 EPS for the current year.

PDS Biotechnology Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.